Subject: On the second European Panel on the Appropriateness of Crohn's disease Therapy (EPACT-II)

On the second European Panel on the Appropriateness of Crohn's disease Therapy (EPACT-II)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In an era of evidence based medicine, what constitutes “evidence”? For aficionados, a large, statistically powered clinical trial that enrolls a specific type of patient, randomized to receive one of several alternative therapies, being evaluated in a blinded fashion would achieve that status. Even better, if multiple trials examined the same therapy in the same way, then a meta-analysis synthesizing those data provides even better “evidence” for patients and providers. In contrast, the second European Panel on the Appropriateness of Crohn's disease Therapy (EPACT-II) – reported in this issue of the JCC – uses ...
Source: Journal of Critical Care - November 7, 2009 Category: Gastroenterology Authors: Robert W. Dubois Tags: Editorial Source Type: journals